Sign In
Buy ILMN
$205.10
+0.0100 (+0.0049%)
At Close: Jul 31, 2026
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
09:16am, Wednesday, 28'th May 2025
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
09:15am, Wednesday, 28'th May 2025
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illum
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
09:51am, Tuesday, 20'th May 2025
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
11:47am, Monday, 19'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
11:28am, Friday, 16'th May 2025
Carl Icahn is making bold moves from the lab to the tarmac.
Illumina To Webcast Upcoming Investor Conference
04:05pm, Wednesday, 14'th May 2025
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends
10:21am, Tuesday, 13'th May 2025
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
09:15am, Tuesday, 13'th May 2025
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps,
Illumina Analysts Lower Their Forecasts After Q1 Results
11:28am, Monday, 12'th May 2025
Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
10:58pm, Saturday, 10'th May 2025
Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in l
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
09:50am, Friday, 09'th May 2025
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
09:01pm, Thursday, 08'th May 2025
Illumina, Inc. (NASDAQ:ILMN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:30pm, Thursday, 08'th May 2025
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
07:00pm, Thursday, 08'th May 2025
Illumina (ILMN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.09 per share a year ago.
Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics
10:21am, Monday, 05'th May 2025
Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte
